Skip to main content Help with accessibility Skip to main navigation

UPADACITINIB prolonged-release tablets (RINVOQ®▼) for ulcerative colitis

CCG Approval Status:

Date Added: 23 - Feb - 2023

The Cheshire and Merseyside Interim Area Prescribing Group recommends the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ®▼), by specialists only, for treating moderately to severely active ulcerative colitis in adults in accordance with NICE TA856.

NHS Cheshire and Merseyside APPROVED